| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on September 16, 2004
Accepted on November 1, 2004
Department of Physiology, Göteborg University, Box 434, S-405 30 Göteborg, Sweden; Department of Internal Medicine, Division of Endocrinology, Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, S-413 45 Göteborg, Sweden; Department of Medicine, Lund University, Lund, Sweden; AstraZeneca R&D, Mölndal, Sweden
* To whom correspondence should be addressed. E-mail: bob.olsson{at}medic.gu.se.
It is known that bovine growth hormone (bGH) transgenic mice have increased body mass, insulin resistance and altered lipoprotein metabolism when fed a normal diet. In this study, the effects of 8 weeks of high fat diet were investigated in 6 month old male bGH mice. While littermate controls had unchanged energy intake, energy intake was higher in the bGH mice on a high fat diet than on a low fat diet. Nevertheless, the bGH mice were resistant to diet-induced weight gain and only in the bGH mice did the high fat diet result in increased energy expenditure. Glucose oxidation was higher in the bGH mice compared with littermate controls on both a high fat and normal diet. In addition, the bGH mice had 0.5 C higher body temperature throughout the day and increased hepatic UCP2 expression; changes that were unaffected by the high fat diet. On a high fat diet, the effect of bGH over-expression on serum triglycerides and apoB was opposite to that on a normal diet, resulting in higher serum concentrations of triglycerides and apoB compared with littermate controls. Increased serum triglycerides were explained by decreased triglyceride clearance. The high fat diet led to diabetes only in the bGH mice.
In conclusion, bGH transgenic mice were resistant to diet-induced obesity in spite of hyperphagia, possibly due to increased energy expenditure. On a high fat diet, bGH mice became dyslipidemic and diabetic and thereby more accurately reflect the metabolic situation in acromegalic patients.
This article has been cited by other articles:
 |
|
 |
|
  J.-P. del Rincon, K. Iida, B. D. Gaylinn, C. E. McCurdy, J. W. Leitner, L. A. Barbour, J. J. Kopchick, J. E. Friedman, B. Draznin, and M. O. Thorner Growth Hormone Regulation of p85{alpha} Expression and Phosphoinositide 3-Kinase Activity in Adipose Tissue: Mechanism for Growth Hormone-Mediated Insulin Resistance Diabetes, June 1, 2007; 56(6): 1638 - 1646. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. McKay, R. Kaaks, M. Johansson, C. Biessy, F. Wiklund, K. Balter, H.-O. Adami, C. Boillot, L. Gioia-Patricola, F. Canzian, et al. Haplotype-Based Analysis of Common Variation in the Growth Hormone Receptor Gene and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., January 1, 2007; 16(1): 169 - 173. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Berryman, E. O. List, D. T. Kohn, K. T. Coschigano, R. J. Seeley, and J. J. Kopchick Effect of Growth Hormone on Susceptibility to Diet-Induced Obesity Endocrinology, June 1, 2006; 147(6): 2801 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Garcia, I. Wernstedt, A. Berndtsson, M. Enge, M. Bell, O. Hultgren, M. Horn, B. Ahren, S. Enerback, C. Ohlsson, et al. Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes, May 1, 2006; 55(5): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Z. Michaylira, N. M. Ramocki, J. G. Simmons, C. K. Tanner, K. K. McNaughton, J. T. Woosley, C. J. Greenhalgh, and P. K. Lund Haplotype Insufficiency for Suppressor of Cytokine Signaling-2 Enhances Intestinal Growth and Promotes Polyp Formation in Growth Hormone-Transgenic Mice Endocrinology, April 1, 2006; 147(4): 1632 - 1641. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
